Analyst Price Targets — TFX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 25, 2026 10:19 am | Mike Matson | Needham | $170.00 | $138.31 | StreetInsider | Teleflex (TFX) PT Raised to $170 at Needham |
| August 11, 2026 12:45 pm | — | UBS | $158.00 | $135.91 | TheFly | Teleflex price target raised to $158 from $145 at UBS |
| August 10, 2026 2:48 pm | Richard Newitter | Truist Financial | $150.00 | $134.71 | TheFly | Teleflex price target raised to $150 from $143 at Truist |
| July 31, 2026 9:02 am | Mike Matson | Needham | $159.00 | $132.30 | StreetInsider | Teleflex (TFX) PT Raised to $159 at Needham |
| July 28, 2026 10:46 am | Patrick Wood | UBS | $145.00 | $131.05 | TheFly | Teleflex initiated with a Neutral at UBS |
| July 8, 2026 8:27 pm | Vik Chopra | BMO Capital | $159.00 | $130.35 | TheFly | Teleflex initiated with an Outperform at BMO Capital |
| June 8, 2026 8:00 am | Jason Bednar | Piper Sandler | $160.00 | $129.84 | StreetInsider | Piper Sandler Assumes Coverage and Upgrades Teleflex (TFX) to Overweight |
| May 8, 2026 1:15 pm | Jayson Bedford | Raymond James | $150.00 | $131.91 | TheFly | Teleflex price target raised to $150 from $128 at Raymond James |
| May 8, 2026 11:20 am | — | Mizuho Securities | $140.00 | $131.68 | TheFly | Teleflex price target raised to $140 from $135 at Mizuho |
| May 8, 2026 9:29 am | Shagun Singh | RBC Capital | $155.00 | $131.68 | TheFly | Teleflex upgraded to Outperform from Sector Perform at RBC Capital |
Latest News for TFX
Bank of New York Mellon Corp purchased a new position in Teleflex Incorporated (NYSE: TFX) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 263,156 shares of the medical technology company's stock, valued at approximately $33,358,000. Bank of
TFX's Vascular growth, Interventional expansion and improved leverage support its outlook, while currency volatility remains a key risk.
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Valuation is improving for Teleflex, but slower Vascular Intervention integration and margin pressure keep execution risks in focus.
TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.